Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AFT PharmaceuticalsASX:AFP -0.26%76 Operating Cash Flow per Share is A$-0.08 as of Mar. 2026. GuruFocus rates ASX:AFP with a GF Score™ of 76/100 and a GF Value™ of A$3.37 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 762 Drug Manufacturers companies, AFT Pharmaceuticals ranks worse than 131233.46% on this metric.
AFT Pharmaceuticals's operating cash flow per share for the
six
months ended in Mar. 2026 was A$-0.08.
AFT Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2026 was A$-0.08.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of AFT Pharmaceuticals was -172.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for AFT Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:
During the past 11 years, AFT Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 239.90% per year. The lowest was -10.10% per year. And the median was 64.20% per year.
ASX:AFP's 3-Year OCF Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.15 * Ranked among companies with meaningful 3-Year OCF Growth Rate only.
AFT Pharmaceuticals Operating Cash Flow per Share Related Terms
AFT Pharmaceuticals Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for AFT Pharmaceuticals's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AFT Pharmaceuticals Operating Cash Flow per Share Chart
ASX:AFP vs ZTS, UTHR, VTRS: Operating Cash Flow per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals Price-to-Operating-Cash-Flow vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of A$-0.08 mean?
AFT Pharmaceuticals (ASX:AFP) has a Operating Cash Flow per Share of A$-0.08 as of Mar. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on AFT Pharmaceuticals and its competitors. According to the industry distribution chart, AFT Pharmaceuticals ranks #999999 out of 762 companies in the Drug Manufacturers industry.
Is AFT Pharmaceuticals' Operating Cash Flow per Share too high?
AFT Pharmaceuticals' current Operating Cash Flow per Share is A$-0.08. Based on the distribution chart, AFT Pharmaceuticals ranks #999999 out of 762 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, AFT Pharmaceuticals has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Operating Cash Flow per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #999999 out of 762 companies for Operating Cash Flow per Share. This places AFT Pharmaceuticals in the lower half of its industry. The industry median Operating Cash Flow per Share is 7.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Drug Manufacturers company?
The median Operating Cash Flow per Share among Drug Manufacturers companies is 7.15, based on 762 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on AFT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Operating Cash Flow per Share is 7.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current Operating Cash Flow per Share is A$-0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (ASX:AFP) is currently considered Modestly Overvalued. The stock's GF Value™ is A$3.37, compared to a current price of A$3.86 — trading 14.5% above its estimated fair value. The current Operating Cash Flow per Share is A$-0.08. AFT Pharmaceuticals' overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For AFT Pharmaceuticals (ASX:AFP), the current Operating Cash Flow per Share is A$-0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (ASX:AFP) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be overvalued.
The current stock price of A$3.86 is trading 14.5% above its estimated GF Value™ of A$3.37.
GuruFocus considers AFT Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ASX:AFP:
Operating Cash Flow per Share: A$-0.08
GF Value™: A$3.37 vs. price of A$3.86 (14.5% above fair value)
No single metric tells the full story. See the ASX:AFP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
76GF Score
Get the complete analysis for ASX:AFP
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AFP has been successfully added to your 
